KMT2A and leukemia: To investigate whether the anti-leukemic effect of the drug is potentiated when combined with HDAC targeting, we tested the combination of CBL0137 and the HDAC inhibitor panobinostat in a highly aggressive, transplantable mouse model of MLL-AF9 (KMT2A:MLLT3) leukemia.